Digital health innovators, Lifelight and PocDoc, have been announced as the successful companies of the Novartis Biome UK Heart Health Catalyst 2022.
The CW Innovation programme, jointly led by CW+ and Chelsea and Westminster Hospital NHS Foundation Trust, partnered with Novartis Pharmaceuticals UK, Medtronic ltd and RYSE Asset Management to launch the Catalyst back in July.
Lifelight and PocDoc will receive support to scale their innovative digital solutions for cardiovascular disease (CVD) care. The companies were selected by a prestigious judging panel at the Novartis Biome UK Heart Health Catalyst 2022 Pitchfest, hosted at the Healthcare Excellence Through Technology (HETT) Show at ExCeL in London on 27 and 28 September.
Through a world-first partnership spanning different industries, the Catalyst aims to transform CVD patient pathways, harnessing the power of data and digital to empower patients to improve their heart health, and to help prevent ill-health.
The initiative provides Lifelight and PocDoc with access to the Novartis Biome UK eco-system, and the CW Innovation programme will work to set up and deliver a pilot evaluation of their innovations. The companies will also have the opportunity to secure investment of up to £3 million provided by RYSE Asset Management.
The companies have been selected because of their potential to remodel patient care pathways for CVD, offering novel approaches to non-invasive lipid testing and at-home blood pressure management.
Chris Chaney, the Chief Executive Officer at CW+ and co-lead of CW Innovation, said: “We would like to congratulate the winners and all the finalists of the Novartis Biome UK Heart Health Catalyst 2022. It has been a pleasure to work in collaboration with Novartis UK and partners on this exciting initiative, and we look forward to providing Lifelight and PocDoc with the opportunity to test and scale their innovation at Chelsea and Westminster Hospital NHS Foundation Trust to help improve the care and experience of CVD patients.”
For further information on the Novartis Biome UK Heart Health Catalyst 2022 and the winning innovations click here.